Individuation of omogeneous diagnostic subtypes and targeted pharmacological strategies have always been the basis of our research concerning Eating Disorders.Many of our studies assessed that best efficacy could be obtained when drugs are chosen following specific clinical criteria.Recent neuropharmacological substances disponibility lead us to reconsider therapeutical efficacy analysis of more than 300 patients affected by Eating Disorders treated, during last years, with conventional antidepressants (clomipramine, fluoxetine, paroxetine, levosulpiride).In this study we focus our research on the new drugs effects (citalopram, amisulpride) on particular DSM IV classified Eating Disorders diagnostic subtypes.